Age-stratified conditioning regimens to improve outcomes in haploidentical stem cell transplant for myelodysplastic syndrome

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This Phase 2 interventional trial enrolls adults with myelodysplastic syndrome who are planned for T-cell-replete haploidentical hematopoietic stem cell transplantation. Participants aged 55 and older receive a reduced-toxicity Bu/Flu/Cy/ATG conditioning, while those younger than 55 receive a standard myeloablative Bu/Cy+ATG regimen, followed by uniform post-transplant care. The study prospectively characterizes 1-year transplant-related mortality and evaluates engraftment, graft-versus-host disease, infection, relapse, survival, and conditioning-related organ toxicity. Primary aim is to understand how age-stratified conditioning influences transplant-related outcomes across all enrolled patients. Safety and feasibility data will inform future optimization of conditioning for haploidentical transplants in MDS.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients who had low- and intermediate-risk MDS without ISD nor URD receiving haploidentical hematopoietic stem cell transplantation

Exclusion Criteria:

* Patients having ISD or URD; patients having high-risk MDS; patients with active infection; patients with poor compliance; patients with organ failure

Where it's running

• Peking University People's Hospital, Beijing Lu Daopei Hematology Hospital, Hebei Yanda Lu Daopei Hospital, Nanfang Hospital, Southern Medical University
  Beijing, China Recruiting

Study contacts

• Principal investigator: Xiao-Jun Huang — Peking University Institute of Hematology
• Study coordinator: Yu Wang
• Email: ywyw3172@sina.com
• Phone: 8610-8832-6005

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• FXS0683 in relapsed or refractory blood cancers

  This first‑in‑human study tests FXS0683 in adults with relapsed or refractory B‑cell lymphoma, AML, MDS, or ALL to see if it is safe, how the drug behaves in the body, and whether it shows any antitumor activity.

  Recruiting Phase 1 Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. · Tianjin, Tianjin Municipality · NCT07616089

• Brain network changes in adults with anemia measured by fNIRS

  This project will use functional near-infrared spectroscopy (fNIRS) to see if brain network connections are altered in adults aged 18–65 who have anemia.

  Recruiting Institute of Hematology & Blood Diseases Hospital, China · Tianjin, Tianjin Municipality · NCT07578675

• Cord blood transplant for children and young adults with blood cancers.

  This study will test whether a cord blood transplant given as a first or second transplant can help children and young adults with leukemia, myelodysplasia, or lymphoma who lack a matched donor.

  Recruiting Phase 2 Memorial Sloan Kettering Cancer Center · New York, New York · NCT07566377

• Reduced-intensity donor stem cell transplant with treosulfan/fludarabine and post-transplant cyclophosphamide for leukemia and MDS

  This trial tests a lower-intensity donor stem cell transplant using treosulfan plus fludarabine with post-transplant cyclophosphamide to try to reduce toxicity and prevent graft-versus-host disease in people aged 2–75 with acute leukemias or myelodysplastic syndromes.

  Recruiting Phase 2 Masonic Cancer Center, University of Minnesota · Minneapolis, Minnesota · NCT07493538

• Electronic mindfulness-based music therapy for patients receiving stem cell transplantation

  This trial tests an eHealth mindfulness-based music therapy to see if it improves quality of life and reduces symptoms for adults undergoing stem cell transplantation.

  Recruiting University of Miami · Miami, Florida · NCT07469592

• TAK-226 for anemia in lower-risk MDS in Japanese patients

  This trial tests TAK-226 to see if it improves transfusion-dependent anemia in Japanese adults with lower-risk myelodysplastic syndromes.

  Recruiting at 11 sites Phase 2 Takeda · Tokyo, Bunkyo-ku and 20 other locations · NCT07319845

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.